ProCE Banner Activity

Optimizing ART With Novel HIV Agents

Podcast Episodes

Listen as Gregory Huhn, MD, MPHTM, discusses a case study of a person with HIV and multiclass resistance, exploring when and how to consider agents with novel mechanisms of action.

Released: August 19, 2024

Expiration: August 18, 2025

Share

Faculty

Gregory Huhn

Gregory Huhn, MD, MPHTM

Interim Chief, Division of Infectious Diseases
Senior Director of HIV Services
Cook County HIV Integrated Programs
Interim Medical Director, The RMR CORE Center
Professor, Division of Infectious Diseases
Rush University Medical Center
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from ViiV Healthcare.

ViiV Healthcare

Disclosure

Primary Author

Gregory Huhn, MD, MPHTM

Interim Chief, Division of Infectious Diseases
Senior Director of HIV Services
Cook County HIV Integrated Programs
Interim Medical Director, The RMR CORE Center
Professor, Division of Infectious Diseases
Rush University Medical Center
Chicago, Illinois

Gregory Huhn, MD, MPHTM: consultant/advisor/speaker: Gilead, Merck, ViiV; researcher: Gilead, Janssen, Lilly, Ridgeback, ViiV.